Stanford type B aortic dissection patients with normally hypotensive medical therapy and pitavastatin treatment effect.
- Conditions
- Stanford type B acute aortic dissection patients transported within 48 hours of symptom onset , adaptable normally hypotensive medical therapy.
- Registration Number
- JPRN-UMIN000000685
- Lead Sponsor
- Cardiovascular Surgery, Tohoku University, Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
(1)Patients with the total diameter of descending aorta (minor axis) by CT angiography more than 50mm. (2)Marfan's syndrome patients (3)Patients with continuous pain. (4)Patients with unstable vital signs. (5)Patients with signs or symptoms of organ ischemia (6)Fasting serum levels of TC >/= 250 mg/dL. (7)Known hypersensitivity or history of clinically significant adverse reactions to any component of study drugs. (8)Patients with hepatopathy (ALT >/=100 IU/L) or biliary obstruction with the following conditions - acute hepatitis, acute exacerbation of chronic hepatitis, hepatic cirrhosis, hepatoma, jaundice. (9)Pregnant, possibly pregnant, or lactating. (10)Patients with significant renal dysfunction (serum creatinine >/= 2.0 mg/dL) or renal dialysis. (11)Patient who is judged by the investigator to be inappropriate for inclusion in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percent change and absolute change in the total diameter of the descending aorta (minor axis) by CT angiography
- Secondary Outcome Measures
Name Time Method Percent change and absolute change in the following items (1)Threatened rupture (2)Surgical operation (3)Serum lipid profile (LDL-C, triglyceride, HDL-C) (4)Serum creatinine (5)Correlation with the total diameter of descending aorta (minor axis) and serum lipid profile or serum creatinine (6)All-cause mortalities (7)Evaluation of adverse events (8)Laboratory test abnormalities